Retail giants Tesco and Marks & Spencer both saw a bump in food sales over the vital Christmas period despite both mentioning a challenging economic backdrop.

Tesco said sales in the UK were up 3.2% from last year and it had now notched up its highest market share in more than a decade.

M&S said that it had seen a record number of customers over Christmas and its food sales were “strong”.

However, sales at its clothing, home and beauty business fell, with M&S blaming the decline on lower footfall on the High Street and lingering issues from last year’s cyber-attack.

M&S suffered a sales fall of almost 3% in its fashion, home and beauty products which it said was still suffering from stock and inventory issues following the cyber-attack.

Chief executive Stuart Machin said: “Food sales were strong and the business continues to outperform, hitting a new market share milestone in the period.

“Fashion, Home & Beauty is getting back on track as we work through the tail end of recovery,” he added.

Tesco boss Ken Murphy said he was “delighted” with the supermarket’s performance over Christmas amid “intense” competition.

He highlighted the performance of the Tesco Finest range, which saw sales growth of 13%.

The supermarket is now expecting to report annual operating profits at the upper end of the £2.9bn-£3.1bn range it predicted in October.

“Tesco has seen a consistently strong performance over the last couple of years really, where it’s really focused on price,” said Sofie Willmott, associate director at GlobalData Retail.

She said that by price-matching Aldi, and offering lower prices to its Clubcard holders, Tesco had “managed to retain its number one position at the top of the market”, despite heavy discounting on some of its products to compete with rivals.

“It also saw very good performance in its Finest range where shoppers are maybe not eating out as much or treating themselves,” she added.

When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.

But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.

A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.

They have been found to help people lose between 15-20 percent of their body weight.

“This all appears to be a good news story,” said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.

However, recent data has suggested that “around half of people discontinue these medications within a year,” she told a press conference.

This might be because of common side effects such as nausea or the price — these drugs can cost over $1,000 a month in the US.

So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.

Six of the clinical trials involved semaglutide — the ingredient used in Novo Nordisk’s brands Ozempic and Wegovy — and tirzepatide used for Eli Lilly’s Mounjaro and Zepbound.

While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.

However, after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.

The researchers projected that the participants would return to their original weight in 18 months.

Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.

People who were instead put on programmes that included diet and exercise — but not drugs — lost significantly less weight. However it took an average of four years for them to regain their lost kilos.

This meant that people taking the drugs regained their weight four times faster.

Starting point, not a cure

“Greater weight loss tends to result in faster weight regain,” lead study author Sam West of Oxford University explained.

But separate analysis showed that weight gain was “consistently faster after medication, regardless of the amount of weight lost in the first place,” he added.

This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.

Jebb emphasised that GLP-1 drugs “are a really valuable tool in obesity treatment — but obesity is a chronic relapsing condition.”

“One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication,” Jebb said.

If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.

“This new data makes it clear they are a starting point, not a cure,” said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.

“Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat,” he said.

The National Electric Power Regulatory Authority (Nepra) has announced a Rs0.62/unit cut in electricity tariffs after issuing a notification applicable to consumers across the country.

According to the notification, the reduction has been decided on account of fuel cost adjustment for November and will be passed on to consumers through their January electricity bills.

It stated that the relief is applicable to all categories of consumers nationwide, including Karachi. However, the authority clarified that lifeline consumers will not benefit from the reduction.

This reduction came a week after the Central Power Purchasing Agency’s (CPPA) requested the Nepra to refund Rs0.72/unit to consumers in January bills, potentially giving consumers relief of over Rs5.6 billion.

Fuel price adjustments are reviewed monthly by Nepra to reflect changes in global fuel prices and generation costs, with the impact passed on to consumers through subsequent billing cycles.

Average base tariff for 2026 issued

Meanwhile, the authority has also unveiled the new average base tariff for January-December 2026, setting it at Rs33.38 per unit, offering modest relief to consumers after years of relentless increases.

Notably, the government has shifted tariff determination from a fiscal-year basis to a calendar-year framework and the rebased consumer-end tariff will come into effect from January 1, 2026.

The Nepra noted that the new tariff is 62 paisa lower compared with the July-December 2025 rate, while the average tariff for the 2025-26 fiscal year stood at Rs34 per unit.

It should be noted that currently, the country’s base tariff stands at Rs31.59 per unit, meaning the newly notified rate is Rs1.79 per unit higher than the existing base tariff.

The total financial requirement of distribution companies (Discos) for 2026 is estimated at Rs3,379 billion, including Rs2,923 billion for electricity procurement and Rs456.15 billion for operational costs and profit margins.

The authority added that annual electricity sales for the year are projected at 101 billion units, and the new tariff will ensure cost recovery while meeting the sector’s financial needs.